These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16689077)

  • 21. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.
    Olevsky OM; Martino S
    Menopause; 2008; 15(4 Suppl):790-6. PubMed ID: 18596600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC
    Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
    Johansen J; Overgaard J; Overgaard M
    Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer chemoprevention gets personal.
    Amir E; Goodwin PJ
    J Clin Oncol; 2011 Jun; 29(17):2296-8. PubMed ID: 21537044
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
    Kondo M; Hoshi SL; Toi M
    Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamoxifen: an enduring star.
    Veronesi U; Maisonneuve P; Decensi A
    J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
    [No Abstract]   [Full Text] [Related]  

  • 29. The science of selective estrogen receptor modulators: concept to clinical practice.
    Jordan VC
    Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raloxifene and risk for stroke based on the framingham stroke risk score.
    Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
    Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK; Ford LG
    Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen in breast cancer: not so easy to write off.
    Munshi A; Singh P
    Breast; 2008 Apr; 17(2):121-4. PubMed ID: 17923407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
    Neves-E-Castro M
    Clin Obstet Gynecol; 2008 Sep; 51(3):607-17. PubMed ID: 18677154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
    Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is raloxifene ready to be used for prevention of breast cancer?
    Powles TJ
    Int J Fertil Womens Med; 2006; 51(5):203-4. PubMed ID: 17269585
    [No Abstract]   [Full Text] [Related]  

  • 38. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 39. Moving forward with breast cancer prevention.
    Chen WY; Rosner B; Colditz GA
    Cancer; 2007 Jun; 109(12):2387-91. PubMed ID: 17464950
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
    Yen TW; Kuerer HM; Ottesen RA; Rouse L; Niland JC; Edge SB; Theriault RL; Weeks JC
    J Clin Oncol; 2007 Aug; 25(22):3251-8. PubMed ID: 17577019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.